NorthWest Biotherapeutics Inc (NWBO)

[Lykiri]

SNO-CAP 2018: RECAPPING THE ANNUAL MEETING AND EDUCATION DAY OF THE SOCIETY FOR NEURO-ONCOLOGY
By Tom Halkin | Published December 17, 2018

Finally, Dr. Linda Liau of UCLA, in discussing her 20 years of experience leading studies of the immunotherapy called DCVax, expressed the need for more careful development and selection of trials endpoints. She noted that endpoints relevant for immunotherapy trials may be different from those for other treatments, and that, in general, relevant surrogate biomarkers of progression-free survival and response are desperately needed in the field to expedite trials.
Coincidently, a recent article – authored by Dr. Erik Sulman, who participates in the Defeat GBM Research Collaborative – details more on this topic.

http://blog.braintumor.org/sno-cap-2018-recapping-the-annual-meeting-and-education-day-of-the-society-for-neuro-oncology/